- Home
- PMVP vs KPTI Comparison
PMVP vs KPTI Comparison
Compare PMVP & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- KPTI
- Stock Information
- Founded
- PMVP 2013
- KPTI 2008
- Country
- PMVP United States
- KPTI United States
- Employees
- PMVP N/A
- KPTI N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- KPTI Health Care
- Exchange
- PMVP Nasdaq
- KPTI Nasdaq
- Market Cap
- PMVP 55.1M
- KPTI 44.5M
- IPO Year
- PMVP 2020
- KPTI 2013
- Fundamental
- Price
- PMVP $1.20
- KPTI $4.39
- Analyst Decision
- PMVP Strong Buy
- KPTI Buy
- Analyst Count
- PMVP 1
- KPTI 6
- Target Price
- PMVP $5.00
- KPTI $48.50
- AVG Volume (30 Days)
- PMVP 278.5K
- KPTI 52.3K
- Earning Date
- PMVP 08-07-2025
- KPTI 08-05-2025
- Dividend Yield
- PMVP N/A
- KPTI N/A
- EPS Growth
- PMVP N/A
- KPTI N/A
- EPS
- PMVP N/A
- KPTI N/A
- Revenue
- PMVP N/A
- KPTI $142,126,000.00
- Revenue This Year
- PMVP N/A
- KPTI $2.09
- Revenue Next Year
- PMVP N/A
- KPTI $12.90
- P/E Ratio
- PMVP N/A
- KPTI N/A
- Revenue Growth
- PMVP N/A
- KPTI 1.19
- 52 Week Low
- PMVP $0.81
- KPTI $3.51
- 52 Week High
- PMVP $1.82
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- PMVP 57.96
- KPTI 45.76
- Support Level
- PMVP $0.96
- KPTI $4.12
- Resistance Level
- PMVP $1.14
- KPTI $4.85
- Average True Range (ATR)
- PMVP 0.07
- KPTI 0.31
- MACD
- PMVP -0.00
- KPTI 0.04
- Stochastic Oscillator
- PMVP 65.28
- KPTI 36.99
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.